BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 33202286)

  • 1. Kanglexin, a new anthraquinone compound, attenuates lipid accumulation by activating the AMPK/SREBP-2/PCSK9/LDLR signalling pathway.
    Li X; Hu X; Pan T; Dong L; Ding L; Wang Z; Song R; Wang X; Wang N; Zhang Y; Wang J; Yang B
    Biomed Pharmacother; 2021 Jan; 133():110802. PubMed ID: 33202286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Daming capsule, a hypolipidaemic drug, lowers blood lipids by activating the AMPK signalling pathway.
    Bian Y; Li X; Li X; Ju J; Liang H; Hu X; Dong L; Wang N; Li J; Zhang Y; Yang B
    Biomed Pharmacother; 2019 Sep; 117():109176. PubMed ID: 31387185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of Adiponectin Receptor Regulates Proprotein Convertase Subtilisin/Kexin Type 9 Expression and Inhibits Lesions in ApoE-Deficient Mice.
    Sun L; Yang X; Li Q; Zeng P; Liu Y; Liu L; Chen Y; Yu M; Ma C; Li X; Li Y; Zhang R; Zhu Y; Miao QR; Han J; Duan Y
    Arterioscler Thromb Vasc Biol; 2017 Jul; 37(7):1290-1300. PubMed ID: 28546220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aloe-emodin exerts cholesterol-lowering effects by inhibiting proprotein convertase subtilisin/kexin type 9 in hyperlipidemic rats.
    Su ZL; Hang PZ; Hu J; Zheng YY; Sun HQ; Guo J; Liu KY; Du ZM
    Acta Pharmacol Sin; 2020 Aug; 41(8):1085-1092. PubMed ID: 32203084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Electroacupuncture mitigates hyperlipidemia via improving cholesterol metabolism mediated by SCAP/SREBP-2 signaling in liver tissue in rats].
    Wu H; Zhang ZQ; Chen L; Liao S; Wang XF; Lin W
    Zhen Ci Yan Jiu; 2023 Apr; 48(4):325-30. PubMed ID: 37186195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chitosan oligosaccharides enhance lipid droplets via down-regulation of PCSK9 gene expression in HepG2 cells.
    Yang X; Zhang J; Chen L; Wu Q; Yu C
    Exp Cell Res; 2018 May; 366(2):152-160. PubMed ID: 29548750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alginate oligosaccharide enhances LDL uptake via regulation of LDLR and PCSK9 expression.
    Yang JH; Bang MA; Jang CH; Jo GH; Jung SK; Ki SH
    J Nutr Biochem; 2015 Nov; 26(11):1393-400. PubMed ID: 26320675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose-dependent effects of siRNA-mediated inhibition of SCAP on PCSK9, LDLR, and plasma lipids in mouse and rhesus monkey.
    Jensen KK; Tadin-Strapps M; Wang SP; Hubert J; Kan Y; Ma Y; McLaren DG; Previs SF; Herath KB; Mahsut A; Liaw A; Wang S; Stout SJ; Keohan C; Forrest G; Coelho D; Yendluri S; Williams S; Koser M; Bartz S; Akinsanya KO; Pinto S
    J Lipid Res; 2016 Dec; 57(12):2150-2162. PubMed ID: 27707816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diet-induced hepatic steatosis abrogates cell-surface LDLR by inducing
    Lebeau PF; Byun JH; Platko K; MacDonald ME; Poon SV; Faiyaz M; Seidah NG; Austin RC
    J Biol Chem; 2019 Jun; 294(23):9037-9047. PubMed ID: 31004037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Naringin Activates AMPK Resulting in Altered Expression of SREBPs, PCSK9, and LDLR To Reduce Body Weight in Obese C57BL/6J Mice.
    Sui GG; Xiao HB; Lu XY; Sun ZL
    J Agric Food Chem; 2018 Aug; 66(34):8983-8990. PubMed ID: 30092639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diallyl disulfide improves lipid metabolism by inhibiting PCSK9 expression and increasing LDL uptake via PI3K/Akt-SREBP2 pathway in HepG2 cells.
    Wu YR; Li L; Sun XC; Wang J; Ma CY; Zhang Y; Qu HL; Xu RX; Li JJ
    Nutr Metab Cardiovasc Dis; 2021 Jan; 31(1):322-332. PubMed ID: 33500108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulatory mechanism of mineral-balanced deep sea water on hypocholesterolemic effects in HepG2 hepatic cells.
    Lee KS; Kwon YS; Kim S; Moon DS; Kim HJ; Nam KS
    Biomed Pharmacother; 2017 Feb; 86():405-413. PubMed ID: 28012395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Tanshinone IIA on the modulation of miR‑33a and the SREBP‑2/Pcsk9 signaling pathway in hyperlipidemic rats.
    Jia L; Song N; Yang G; Ma Y; Li X; Lu R; Cao H; Zhang N; Zhu M; Wang J; Leng X; Cao Y; Du Y; Xu Y
    Mol Med Rep; 2016 Jun; 13(6):4627-35. PubMed ID: 27082100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Irisin inhibits PCSK9 expression through activating AMPK-SREBP2 pathway.
    Xu R; Liu Q; Ma X; Hou J
    Biochem Biophys Res Commun; 2022 Nov; 630():77-83. PubMed ID: 36152348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hexacosanol reduces plasma and hepatic cholesterol by activation of AMP-activated protein kinase and suppression of sterol regulatory element-binding protein-2 in HepG2 and C57BL/6J mice.
    Lee JH; Jia Y; Thach TT; Han Y; Kim B; Wu C; Kim Y; Seo WD; Lee SJ
    Nutr Res; 2017 Jul; 43():89-99. PubMed ID: 28676202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peroxisome Proliferator-activated receptor γ activation by ligands and dephosphorylation induces proprotein convertase subtilisin kexin type 9 and low density lipoprotein receptor expression.
    Duan Y; Chen Y; Hu W; Li X; Yang X; Zhou X; Yin Z; Kong D; Yao Z; Hajjar DP; Liu L; Liu Q; Han J
    J Biol Chem; 2012 Jul; 287(28):23667-77. PubMed ID: 22593575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apigenin Ameliorates Insulin Resistance and Lipid Accumulation by Endoplasmic Reticulum Stress and SREBP-1c/SREBP-2 Pathway in Palmitate-Induced HepG2 Cells and High-Fat Diet-Fed Mice.
    Wu L; Guo T; Deng R; Liu L; Yu Y
    J Pharmacol Exp Ther; 2021 Apr; 377(1):146-156. PubMed ID: 33509902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of neolignans with PCSK9 downregulatory and LDLR upregulatory activities from Penthorum chinense and the potential in cholesterol uptake by transcriptional regulation of LDLR via SREBP2.
    Chae HS; Pel P; Cho J; Kim YM; An CY; Huh J; Choi YH; Kim J; Chin YW
    J Ethnopharmacol; 2021 Oct; 278():114265. PubMed ID: 34111537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
    Urban D; Pöss J; Böhm M; Laufs U
    J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polydatin ameliorates lipid and glucose metabolism in type 2 diabetes mellitus by downregulating proprotein convertase subtilisin/kexin type 9 (PCSK9).
    Wang Y; Ye J; Li J; Chen C; Huang J; Liu P; Huang H
    Cardiovasc Diabetol; 2016 Feb; 15():19. PubMed ID: 26833058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.